Entero Therapeutics, Inc.
ENTO
$0.531
$0.04679.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 89.71% | -374.17% | 70.70% | -258.20% | 235.77% |
| Total Depreciation and Amortization | -- | -2,738.46% | -96.32% | 186.99% | 68.49% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -- | -- |
| Total Other Non-Cash Items | -98.82% | 5,224.03% | -96.11% | 152.85% | -6,222.73% |
| Change in Net Operating Assets | -77.55% | 164.01% | 258.49% | -67.21% | -8.78% |
| Cash from Operations | -377.32% | 90.72% | 46.43% | 7.90% | -8.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | 117.64% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | 100.00% | 26.31% | -6.64% | -- |
| Issuance of Common Stock | -- | -100.00% | 94.30% | -75.29% | -17.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,301.26% | -102.05% | 127.88% | -79.83% | -22.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.66% | 31.25% | 89.32% | -889.42% | -166.74% |